Log in to search using one of your social media accounts:

 

Nonalcoholic fatty liver disease increases risk of liver, colorectal, and breast cancers
(Elsevier) Nonalcoholic fatty liver disease (NAFLD) is one of the more common chronic liver diseases worldwide. It is associated with metabolic syndrome (i.e. insulin resistance and diabetes) and predisposes to cardiovascular disease. In a new study published in the Journal of Hepatology, researchers identified links not only between NAFLD and hepatocellular carcinoma (HCC), which have been well established, but also to cancers outside the liver, including colorectal and breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2017 Category: Cancer & Oncology Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab). ABP 215 has been recommended for approval for the treatment of certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rec...
Source: Amgen News Release - November 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Sharing Mayo Clinic: Breast cancer patient finds answer in centralized care
Renee Hill had received opinions from other health care facilities but desperately wanted to have her medical care centralized and coordinated. "My gut was telling me Mayo was where I needed to go," she says.? When Renee Hill was diagnosed with breast cancer ? stage 3 invasive ductal carcinoma ? on her birthday in July [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 22, 2017 Category: Databases & Libraries Source Type: news

New drug successful to treat drug-resistant thyroid cancer
According to a study published inOncotarget, palbociclib, normally used in the treatment of breast cancer, can be used to treat papillary thyroid carcinomas that are resistant to vemurafenib.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 19, 2017 Category: Endocrinology Source Type: news

Unrelenting NHS pressure affecting cancer care, say GPs and nurses
Half of GPs and primary care nurses not confident NHS workforce can provide adequate care Related items fromOnMedica Nasopharyngeal carcinoma and sinus cancer UK spends 20% less on cancer treatment than rest of EU Fifteen local NHS transformation projects to get cash boost The genetics of breast cancer Meeting cancer promises and more – a new model for NHS diagnostics? (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 8, 2017 Category: UK Health Source Type: news

Rare Neuroendocrine Breast Cancer Not So Unusual Rare Neuroendocrine Breast Cancer Not So Unusual
Neuroendocrine breast cancer can be indistinguishable from high-grade ductal carcinoma, although treatment is different, and can be missed unless stained specifically for neuroendocrine markers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 7, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine News Source Type: news

Local DCIS Recurrence After Skipping Adjuvant Radiation Local DCIS Recurrence After Skipping Adjuvant Radiation
Omitting radiation after lumpectomy for pure ductal carcinoma in situ (DCIS) does not improve the chance of breast preservation in case of local recurrence, researchers from Canada have observed.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 6, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

COUNTERPOINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?
To universally recommend breast irradiation for all women after excision of DCIS lesions ignores information now available to us that can spare the majority of women with DCIS the downsides of RT, but be applied in the treatment of DCIS patients at greater risk for invasive disease. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: William C. Wood, MD Tags: Breast Cancer Oncology Journal Source Type: news

POINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?
At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: Camille Berriochoa, MD Carisa Bohnak, BS Chirag Shah, MD Nicole Chahine, BS Tags: Breast Cancer Oncology Journal Source Type: news

Fibromatosis-like Spindle Cell Carcinoma of the Breast Fibromatosis-like Spindle Cell Carcinoma of the Breast
This case describes the clinical and imaging findings of a rare triple negative, fibromatosis-like metaplastic spindle cell breast carcinoma.Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 7, 2017 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Case: Traumatic Neuroma of the Breast After Mastectomy Case: Traumatic Neuroma of the Breast After Mastectomy
What was the etiology of this small mass found on screening mammogram in a woman with a history of invasive ductal carcinoma and modified radical mastectomy?Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2017 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

EMA Panel Likes Breast and Kidney Cancer Drugs EMA Panel Likes Breast and Kidney Cancer Drugs
The Committee for Medicinal Products for Human Use recommended approval of ribociclib for advanced HER+/HER2- breast cancer and tivozanib for advanced renal cell carcinoma.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Dogs help in breast carcinoma research
(University of Zurich) Cancer of the mammary glands in dogs is very similar to human breast carcinoma. For this reason, treatment methods from human medicine are often used for dogs. Conversely, scientific knowledge gained from canine mammary tumors may also be important to human medicine. Researchers from the University of Zurich were able to show how similar these tumors are in both dogs and humans. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 6, 2017 Category: Cancer & Oncology Source Type: news

Methanol from African Plants Kills Mesothelioma Cells
This study provides evidences of the cytotoxicity of the tested plant extract and highlights the good activity of Elephantopus mollis and Kalanchoe crenata,” Kuete wrote. “They deserve more exploration to develop novel cytotoxic drugs.” The post Methanol from African Plants Kills Mesothelioma Cells appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - June 2, 2017 Category: Environmental Health Authors: Matt Mauney Tags: African medicinal plants African whitewood apoptosis mesothelioma BMC Complementary and Alternative Medicine breast cancer Cameroon cancer chemotherapy colon cancer cytotoxicity against mesothelioma cells doxorubicin Dr. Victor Kuete Source Type: news

Data for KEYTRUDA ® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. Research with KEYTRUDA in Monotherapy and in Combination Includes Findings in Non-Small Cell Lung Cancer (NSCLC), Melanoma, Urothelial Carcinoma, Microsatellite-Instability High (MSI-H) Cancers, Gastric Cancer and Breast Cancer New Overall Survival Data to be Presented in NSCLC, Melanoma and Urothelial CarcinomaKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, will be presented at the 53rd An...
Source: Merck.com - Corporate News - May 17, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK NYSE: MRK Source Type: news

Why You Should Always Ask For A Second Opinion
Two years ago, when actress-singer Rita Wilson was 58, she underwent a double mastectomy and had this to say about it: Getting a second opinion saved her life. Wilson was right to insist on a second opinion, according to a Mayo Clinic study released this month. Of 286 patients who sought a second opinion from the clinic over a two-year period, 88 percent received a diagnosis that was either modified or completely different from the first one they received. Sixty-six percent of patients received a refined diagnosis and 22 percent received a completely different one, the study found.  Only 12 percent received confirmati...
Source: Healthy Living - The Huffington Post - April 26, 2017 Category: Consumer Health News Source Type: news

New drug delivery system shows promise for fighting solid tumors
A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment. Carcinomas that affect the breast, lung, prostate and colon are among these solid-tumor cancers, as are malignancies in the lymphatic system, known as lymphomas, and the much less common sarcomas that arise in connective tissue. (Source: World Pharma News)
Source: World Pharma News - April 4, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Medical News Today: Invasive lobular carcinoma: Symptoms, subtypes, diagnosis, and treatment
Learn about invasive lobular carcinoma, a type of cancer that starts in the milk glands of the breast and can spread to infect other lymph nodes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 31, 2017 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Metaplastic Breast Carcinomas Reveal Overexpression of PDL-1 Metaplastic Breast Carcinomas Reveal Overexpression of PDL-1
This study analyzed the distribution of PD-L1 expression in metaplastic breast carcinoma, a rare and aggressive tumor, in comparison to other subtypes of breast carcinoma.Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Targeting cancer stem cells improves treatment effectiveness and prevents metastasis
This study shows that for the first time, targeting the proliferating tumor mass and dormant cancer stem cells with combination therapy effectively inhibited tumor growth and prevented metastasis compared to monotherapy in mice,” said Wang, who is a member of the UCLA Jonsson Comprehensive Canc er Center and of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. “Our discovery could be applied to other solid tumors such as breast and colon cancer, which also frequently metastasizes to lymph nodes or distant organs.”“With this new and exciting study, Dr. Wang and ...
Source: UCLA Newsroom: Health Sciences - March 9, 2017 Category: Universities & Medical Training Source Type: news

Mayo Clinic tests vaccine to provide immune response against early breast lesion
(Mayo Clinic) Only about 35 percent of precancerous breast lesions morph into cancer if untreated, but physicians cannot identify which lesions are potentially dangerous. So all women diagnosed with ductal carcinoma in situ undergo traditional therapy of surgery and possibly hormonal therapy and radiation. Now, Mayo Clinic researchers are about to test a vaccine that they hope will replace standard therapies and prevent recurrence for some, if not all, these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 1, 2017 Category: Global & Universal Source Type: news

Mayo Clinic to test vaccine designed to provide immune response against early breast lesions
JACKSONVILLE, Fla. ? Only about 35 percent of precancerous breast lesions morph into cancer if untreated, but physicians cannot identify which lesions are potentially dangerous. So all women diagnosed with ductal carcinoma in situ undergo traditional therapy of surgery and possibly hormonal therapy and radiation. Now, Mayo Clinic researchers are about to test a vaccine [...] (Source: Mayo Clinic Florida News)
Source: Mayo Clinic Florida News - January 31, 2017 Category: Hospital Management Source Type: news

New Research Shows Breast Cancer Precursor Treatment Causes Women to Live Longer
This study is particularly important because DCIS treatment includes radiotherapy, which can cause damage to nearby organs More and more people are becoming aware they have DCIS because it is something that shows up in breast cancer screenings—so more women are able to get treated if they have this form of cancer. For more information on the study, please visit “Women treated for precursor of breast cancer can expect to live as long as other women.” Follow NN/LM SCR on Twitter and like us on Facebook. (Source: Network News)
Source: Network News - January 31, 2017 Category: Databases & Libraries Authors: NN/LM South Central Region Tags: Consumer Health General (all entries) Patient Safety Public Health Research Source Type: news

Medical News Today: Women with noninvasive breast cancer live as long as other women
Women diagnosed with ductal carcinoma in situ have a slightly higher risk of dying from breast cancer, but a significantly lower all-mortality risk. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 30, 2017 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Women treated for early signs of breast cancer live LONGER
Women over the age of 50 with ductal carcinoma in situ - a precursor of breast cancer - were 10 per cent more likely to be alive ten years after their diagnosis than health women, Dutch researchers found. (Source: the Mail online | Health)
Source: the Mail online | Health - January 28, 2017 Category: Consumer Health News Source Type: news

Women treated for precursor of breast cancer can expect to live as long as other women
Women over 50 who have been treated for ductal carcinoma in situ (DCIS), a precursor of breast cancer, are more likely to be alive ten years later than women in the general population, according to new research. Researchers say these results should provide reassurance to women who are diagnosed with the disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 27, 2017 Category: Science Source Type: news

Good News for Older Women With Early Form of Breast Cancer
FRIDAY, Jan. 27, 2017 -- Older women treated for a very early form of breast cancer, called ductal carcinoma in situ (DCIS), do not have an overall increased risk of early death compared to their peers, a new study finds. " Being diagnosed with DCIS... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 27, 2017 Category: Journals (General) Source Type: news

Women treated for precursor of breast cancer can expect to live as long as other women
(ECCO-the European CanCer Organisation) Women over 50 who have been treated for ductal carcinoma in situ (DCIS), a precursor of breast cancer, are more likely to be alive ten years later than women in the general population, according to new research presented at the European Cancer Congress 2017. Researchers say these results should provide reassurance to women who are diagnosed with the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2017 Category: Cancer & Oncology Source Type: news

Study: Mammography Results in Overdiagnosis, No Reduction in Advanced Disease
Breast cancer screening was not associated with any reduction in the incidence of advanced cancer, and overdiagnosis of invasive tumors and ductal carcinoma in situ is a common problem, according to a new study conducted in Denmark. (Source: CancerNetwork)
Source: CancerNetwork - January 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Screening Source Type: news

Reoperation Rates 3-Fold Higher After DCIS Than IBC Reoperation Rates 3-Fold Higher After DCIS Than IBC
Patients undergoing breast-conserving surgery had reoperation rates 3 times higher when when their diagnosis was ductal carcinoma in situ (DCIS) than when it was invasive breast cancer (IBC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 9, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New ASTRO Guidelines for APBI in Early-Stage Breast Cancer New ASTRO Guidelines for APBI in Early-Stage Breast Cancer
The new guideline extends the candidates for accelerated partial-breast irradiation (APBI) to younger women and those with ductal carcinoma in situ.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

A Clinicopathologic Analysis of Metaplastic Breast Carcinoma A Clinicopathologic Analysis of Metaplastic Breast Carcinoma
The authors detail the clinicopathologic features, treatment, and outcomes of 45 patients with metastatic breast cancer; most with high-grade, triple negative disease.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 21, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Older DCIS Patients Have Low Rates of Tamoxifen, AI Usage
The initiation of and adherence to tamoxifen or aromatase inhibitors (AIs) such as anastrozole is low among older women with estrogen receptor-positive ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

Young Age and DCIS Tied to Increased Risk of Breast Tumor Recurrence Young Age and DCIS Tied to Increased Risk of Breast Tumor Recurrence
In women ages 40 and younger, the presence of ductal carcinoma in situ (DCIS) next to an invasive tumor is associated with an increased risk of ipsilateral breast tumor recurrence (IBTR), according to a recently published study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 16, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Current Trends in the Management of Ductal Carcinoma In Situ
This review will summarize the current trends in the diagnosis and management of DCIS and will highlight ongoing trials that are shaping future management of this entity. (Source: CancerNetwork)
Source: CancerNetwork - September 15, 2016 Category: Cancer & Oncology Authors: E. Shelley Hwang, MD, MPH Tristen S. Park, MD Tags: Breast Cancer Oncology Journal Review Article Source Type: news

Common breast cancer test may not be worth the cost, UCLA study suggests
A genomic test widely used to help determine whether women with a common form of breast cancer should undergo radiation is not cost effective, according to a new UCLA Jonsson Comprehensive Cancer Center study. The Oncotype DX DCIS test is given to women with ductal carcinoma in situ, which means the cancer has not spread to any other tissues, to help them choose the best treatment by better identifying the potential of tumors to come back.Oncotype DX DCIS reduces the number of women undergoing radiation therapy, which is good because it decreases the number of women exposed to possibly harmful side effects. However, UCLA J...
Source: UCLA Newsroom: Health Sciences - September 13, 2016 Category: Universities & Medical Training Source Type: news

Guidelines Establish Minimum Negative Margins in DCIS
­Three medical organizations including ASCO have issued a guideline on margins in breast conserving surgery for patients with ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - August 18, 2016 Category: Cancer & Oncology Authors: Anna Azvolinsky Tags: Breast Cancer News Source Type: news

New Guidelines Set Safe Surgery Margins for Some Breast Cancers
FRIDAY, Aug. 12, 2016 -- New surgery guidelines for certain breast cancer patients could reduce both unnecessary surgeries and recurrence rates, three U.S. cancer groups say. The guideline is for treatment of women with ductal carcinoma in situ... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 15, 2016 Category: Journals (General) Source Type: news

New DCIS consensus guideline could curb unnecessary breast surgery and reduce health system costs
(American Society for Radiation Oncology) Three leading national cancer organizations today issued a consensus guideline for physicians treating women who have ductal carcinoma in situ (DCIS) treated with breast-conserving surgery with whole breast irradiation. The new guideline has the potential to save many women from unnecessary surgeries while reducing costs to the health care system. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 15, 2016 Category: Cancer & Oncology Source Type: news

Needle biopsy hormone testing unnecessary for DCIS
Patients with ductal carcinoma in situ (DCIS) breast cancer don't need hormone...Read more on AuntMinnie.comRelated Reading: Delayed rad therapy puts women with DCIS at risk ASBrS: No, we're not overtreating DCIS Rates of high-grade DCIS increase with age Various DCIS treatments produce similar survival rates Kopans: JAMA Oncology paper misinterprets DCIS data (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 10, 2016 Category: Radiology Source Type: news

Syracuse University physicists awarded NSF grant to study cancer-cell behavior
(Syracuse University) Three Syracuse University researchers, who focus on theoretical soft condensed matter and biological physics, will investigate new collective mechanisms that establish and maintain tumor boundaries in breast and cervix carcinomas. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 5, 2016 Category: Global & Universal Source Type: news

Living With Cancer: Squamous Cell Carcinoma of the Skin
Squamous cell carcinoma of the skin This common form of skin cancer usually isn't life-threatening, but it can be aggressive in some cases. Learn more and discover which treatments may help. Breast implants and cancer: Any connection? Is there any connection between breast implants and cancer? And if so, how serious is the risk? Learn [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 28, 2016 Category: Databases & Libraries Source Type: news

Are provider-related factors affecting the likelihood of breast preservation?
( The JAMA Network Journals ) Do regional practice patterns for radiotherapy for ductal carcinoma in situ (DCIS) breast cancer increase the likelihood of mastectomy when there is a second breast cancer in women who did not receive radiotherapy at the initial DCIS diagnosis? (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2016 Category: Cancer & Oncology Source Type: news

Dilon updates Navigator gamma probe
Molecular breast imaging developer Dilon Diagnostics has released a new version...Read more on AuntMinnie.comRelated Reading: Dilon highlights molecular breast tomo device at SNMMI Dilon, GE present breast biopsy tool at SBI Dilon signs distribution deal with GE Dilon touts MBI for invasive lobular carcinoma Dilon: Patient wins legal appeal for MBI coverage (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 7, 2016 Category: Radiology Source Type: news

Medical News Today: Aggressive breast cancer identified with new technique
A combination of math and imaging can distinguish aggressive forms of ductal carcinoma in situ - or stage 0 breast cancer - from non-aggressive forms. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2016 Category: Consumer Health News Tags: Breast Cancer Source Type: news

New technology helps ID aggressive early breast cancer
Researchers have developed a new technology that can identify aggressive forms of ductal carcinoma in situ, or stage 0 breast cancer, from non-aggressive varieties. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 30, 2016 Category: Science Source Type: news

New technology helps ID aggressive early breast cancer
(University of Michigan Health System) Researchers at the University of Michigan developed a new technology that can identify aggressive forms of ductal carcinoma in situ, or stage 0 breast cancer, from non-aggressive varieties. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 30, 2016 Category: Global & Universal Source Type: news

After skin cancer surgery, careful reconstruction around eyes and nose
Treatment Terms Plastic and reconstructive surgery Skin cancers Additional SEO Keywords skin cancer surgery, basal cell carcinoma SEO Meta Description Facial reconstruction helped Elizabeth Ann Badgett return to normal after Mohs surgery to remove basal skin cancer from her lower eyelid, cheek and nose. Overview For six months, Elizabeth Ann Badgett, of Clayton, NC, watched a painless, scaly spot appear and disappear on her nose. Each time the spot returned it was larger, until it reached the corner of her left eye. Her primary care doctor referred her to a dermatologist, who dia...
Source: dukehealth.org: Duke Health News - June 21, 2016 Category: Consumer Health News Authors: Anonymous Source Type: news

Dilon highlights molecular breast tomo device at SNMMI
Molecular breast imaging developer Dilon Diagnostics is highlighting new molecular...Read more on AuntMinnie.comRelated Reading: Dilon, GE present breast biopsy tool at SBI Dilon signs distribution deal with GE Dilon touts MBI for invasive lobular carcinoma Dilon: Patient wins legal appeal for MBI coverage Digirad expands relationship with Dilon (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 14, 2016 Category: Radiology Source Type: news